NCT05751018View on ClinicalTrials.gov

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pyrotinib

Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

Trial Locations (1)

100000

RECRUITING

Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER